{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "19857216",
  "DateCompleted": {
    "Year": "2010",
    "Month": "01",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2009",
    "Month": "10",
    "Day": "27"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1111/j.1440-1843.2009.01570.x"
    ],
    "Journal": {
      "ISSN": "1440-1843",
      "JournalIssue": {
        "Volume": "14 Suppl 2",
        "PubDate": {
          "Year": "2009",
          "Month": "Nov"
        }
      },
      "Title": "Respirology (Carlton, Vic.)",
      "ISOAbbreviation": "Respirology"
    },
    "ArticleTitle": "Definition of hospital-acquired pneumonia and characteristics of guidelines in Japan.",
    "Pagination": {
      "StartPage": "S1",
      "EndPage": "S3",
      "MedlinePgn": "S1-3"
    },
    "Abstract": {
      "AbstractText": [
        "Hospital-acquired pneumonia is defined as pneumonia that appears for the first time within 48 h of hospital admission. Special care is needed in treatment because of poor patient conditions, including the underlying disorder, immunocompetence and general status. The 2002 hospital-acquired pneumonia guidelines were reviewed, and the current revisions were made based on those findings with the aim of producing simple and practical guidelines. Differences are seen between hospital-acquired pneumonia in the USA and Japan, and hospital-acquired pneumonia treatment guidelines matched to circumstances in Japan were considered necessary."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "CollectiveName": "Japanese Respiratory Society"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Australia",
    "MedlineTA": "Respirology",
    "NlmUniqueID": "9616368",
    "ISSNLinking": "1323-7799"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Cross Infection"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Japan"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "Methicillin-Resistant Staphylococcus aureus"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Pneumonia"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Practice Guidelines as Topic"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "epidemiology"
      ],
      "DescriptorName": "Staphylococcal Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    }
  ]
}